

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval for Clinical Trial regarding Investigational New Drug of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

18 June 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* for identification purposes only

Stock code: 600196	Stock abbreviation: Fosun Pharma	Announcement No.: Lin 2021-093
Bond code: 143020	Bond abbreviation: 17 Fosun 01	
Bond code: 143422	Bond abbreviation: 18 Fosun 02	
Bond code: 155067	Bond abbreviation: 18 Fosun 03	
Bond code: 155068	Bond abbreviation: 18 Fosun 01	
Bond code: 175708	Bond abbreviation: 21 Fosun 01	

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for

Clinical Trial regarding Investigational New Drug of

a Subsidiary

The board of directors of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Fochon Pharmaceuticals, Ltd.* (“**Fochon Pharmaceutical**”), a controlling subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) has recently received the approval from the National Medical Products Administration of consent to commence clinical trial of FCN-098 capsules (the “**Investigational New Drug**”) for the treatment of advanced malignant tumors. Fochon Pharmaceutical intends to conduct Phase I clinical trial of the Investigational New Drug in the PRC (excluding Hong Kong and Macau SAR and Taiwan Region, hereinafter the same) in due course as and when the conditions permitted.

II. Research Progress of the Investigational New Drug

The Investigational New Drug is a second-generation TRK small molecule inhibitor

independently developed by the Group (i.e. the Company and its controlling subsidiaries/units, hereinafter the same), and is intended to be used for the treatment of patients with advanced solid tumors with NTRK alterations. As at the date of this announcement, there is no second-generation TRK small molecule inhibitor has been approved for marketing worldwide.

As at May 2021, the Group has cumulatively invested in the R&D of the Investigational New Drug in an aggregate amount of approximately RMB17.16 million (unaudited) at this stage.

III. Risk Warning

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to undergo a series of clinical studies in the PRC and approval from the competent national drug review departments before it comes onto the market. There are certain risks in the R&D of the new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and marketing of the new drug is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

The Board of Directors of
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

18 June 2021